Biotechnology
Gene editing, cancer biotechnology, regenerative medicine, longevity science and the evidence moving from laboratories into clinical care.
-
The “Undruggable” Target Gives Way: FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer
The FDA has approved the first broad RAS-targeted medicine for metastatic pancreatic cancer after a randomized Phase 3 trial showed substantially longer survival than standard chemotherapy. The result is important—but it applies to a defined group of patients and is not a cure.
-
CRISPR Nanoparticles Edited Human Blood Stem Cells Inside Mice
Researchers used CD34-targeted lipid nanoparticles to edit human blood-forming stem cells inside humanized mice. The approach reactivated fetal haemoglobin and partly restored neutrophil development—but it remains early, intrafemoral, preclinical research.
-
FDA Approves a Pill That Targets Pancreatic Cancer’s RAS Engine
Daraxonrasib nearly doubled median survival versus chemotherapy in a 500-person Phase 3 trial. Its FDA approval opens a new way to attack one of cancer’s hardest targets—but it is not a cure.
-
Gene-Edited Islet Cells Aim to Escape Immune Rejection
Gene-edited hypoimmune islet cells are designed to produce insulin while hiding from rejection. The approach could unlock scalable cell therapy—but remains early.
-
Can Humans Regrow Teeth? The First Trial Is Only the Beginning
A drug targeting USAG-1 has moved from animal research into early human testing. It is a safety study for congenital tooth absence—not a cure for lost adult teeth.
-
Stem-Cell Islets Helped a Woman Live Without Insulin—What It Really Means
A woman with type 1 diabetes achieved insulin independence after receiving islets made from reprogrammed cells. The result is historic—but highly preliminary.
-
Mini-Tumours in a Dish Could Help Doctors Test Cancer Drugs
Cancer organoids preserve features of a patient’s tumour and can be exposed to many drugs. Here is the evidence, the promise and why routine use remains difficult.
-
The First Alzheimer’s Blood Test Was Cleared—Then Recalled
The first FDA-cleared Alzheimer’s blood test promised easier diagnosis, then selected lots were recalled. Here is what the test can—and cannot—tell us.
-
Pig Kidneys Move From Experiments Toward Human Clinical Trials
Gene-edited pig kidneys are moving toward structured human trials. Here is how xenotransplantation works, why it matters and the safety questions ahead.
-
Gene Therapy Restored Hearing—Now the First Treatment Is Approved
The first gene therapy for OTOF-related hearing loss has FDA approval. Learn how it restores an inner-ear protein, who it is for and what remains unknown.
-
Lab-Grown Blood Has Entered Human Testing—But Donors Still Matter
Lab-grown red blood cells are being compared with donated cells in the RESTORE trial. Learn why the first goal is rare blood support—not replacing donors.
-
Can CAR-T Reset Autoimmune Disease? Early Remissions Raise Big Questions
CAR-T therapy has produced striking early remissions in severe autoimmune disease. Learn how the immune reset works and why larger trials are still essential.